Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy
Open Access
- 1 July 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1619
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity. HCM is characterized by left ventricular hypertrophy and interventricular septal thickening due to sarcomere protein gene mutations. The recent emergence of cardiac myosin inhibitors (CMIs), specifically mavacamten and aficamten, has introduced a paradigm shift in HCM management by directly targeting the hypercontractile state of the disease. This review comprehensively discusses the molecular mechanisms of mavacamten and aficamten, highlighting their biochemical similarities and differences from available data. It evaluates their reported efficacy in completed clinical trials, such as reducing left ventricular outflow tract (LVOT) obstruction, improving functional capacity, and enhancing quality of life in HCM. It further provides insight and updates to ongoing trials of both CMIs. Finally, it compares and elaborates on the safety profiles of mavacamten and aficamten, discussing their favorable safety profiles shown in completed studies. In current clinical practice, only mavacamten is approved for use, and clinical insights concerning both CMIs are limited, but encouraging. In summary, cardiac myosin inhibitors are a promising class of disease-modifying drugs for HCM with proven short-term safety and efficacy, but limited data are available to fully determine their long-term effects and efficacy in diverse patient populations. Ongoing research is necessary to further explore and define their role in HCM management.Keywords
This publication has 51 references indexed in Scilit:
- Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection FractionJAMA Cardiology, 2025
- Sex Differences In Characteristics Of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Initiated On MavacamtenJournal of Cardiac Failure, 2025
- Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Journal of Cardiac Failure, 2024
- Treatment Strategies for Hypertrophic Cardiomyopathy: SurgicalThe American Journal of Cardiology, 2024
- The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic CardiomyopathyCanadian Journal of Cardiology, 2024
- Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?Current Heart Failure Reports, 2023
- Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapyArchives of Cardiovascular Diseases, 2022
- Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European PopulationJAMA Cardiology, 2020
- Anesthesia for Structural Heart InterventionsCardiology Clinics, 2013
- Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adultsThe American Journal of Medicine, 2004